你即將離開本站

並前往https://www.obipharma.com/zh-hant/news-zh-hant/news-2020-zh-hant/%E6%B5%A9%E9%BC%8E%E5%B0%87%E6%96%BC-esmo-asia-2020-%E7%B7%9A%E4%B8%8A%E5%B9%B4%E6%9C%83%E7%99%BC%E8%A1%A8%E6%96%B0%E4%B8%96%E4%BB%A3%E6%8A%97-globo-h-%E6%B2%BB%E7%99%82%E6%80%A7%E7%99%8C%E7%97%87/

OBI Pharma Announces Presentations at ESMO Asia 2020 ...

Presentations to highlight the OBI-833 Phase 1 clinical study results in non-small cell lung cancer (NSCLC) and the dose escalation cohort.

確定！ 回上一頁

查詢 「cancers評價」的人也找了：

  1. cancers投稿經驗
    2.
  2. 科技部期刊黑名單
    3.
  3. Cancers
    4.
  4. Mega journal
    5.
  5. scientific reports評價
    6.
  6. scientific reports升等
    7.
  7. PeerJ 評價
    8.
  8. PLOS ONE 接受率
    9.